Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-400-4 | CAS number: 16324-27-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Started on April 2, 1979.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Old study, but well documented and scientifically acceptable.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 979
- Report date:
- 1979
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- The acute oral LD50 of the test item in rats of both sexes was assessed administering three doses at 5000, 6500, 8000 and 10000 mg/kg bw. Animals were observed over a period of 14 days.
- GLP compliance:
- no
- Remarks:
- Pre GLP
- Test type:
- standard acute method
Test material
- Reference substance name:
- Tetrasodium 4,4'-bis[[4-[(2-hydroxyethyl)amino]-6-(m-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- EC Number:
- 240-400-4
- EC Name:
- Tetrasodium 4,4'-bis[[4-[(2-hydroxyethyl)amino]-6-(m-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- Cas Number:
- 16324-27-9
- Molecular formula:
- C36H32N12Na4O14S4
- IUPAC Name:
- Tetrasodium 2,2'-[(E)-1,2-ethenediyl]bis[5-({4-[(2-hydroxyethyl)amino]-6-[(3-sulfonatophenyl)amino]-1,3,5-triazin-2-yl}amino)benzenesulfonate]
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Tif RAIf (SPF) strain
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: animals were raised on the premises were used for these experiments.
- Age at study initiation: 7 to 8 weeks old.
- Weight at study initiation: males in the range of 168-199 g; females in the range of 159-177 g.
- Housing: during the treatment and observation period the animals were housed in groups of 5 in Macrolon cages (type 3).
- Diet: ad libitum rat food - NAFAG, Gossau SG.
- Water: ad libitum.
- Acclimation period: for a minimum of 4 days.
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2 °C
- Humidity: 55 ± 10 %
- Photoperiod: 10 hours light cycle day.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 2 %
- Details on oral exposure:
- - Volume: 20 ml/kg
- Doses:
- 5000, 6500, 8000 and 10000 mg/kg bw
- No. of animals per sex per dose:
- 5 x sex x group.
- Details on study design:
- - Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes; animals were at random to a necropsy at the end of the observation period.
- Examinations performed: bodyweights were recorded immediately prior to dosing (control weights) and at 7 and 14 days. - Statistics:
- LD50 including 95 % confidence limits were calculated by the logit model.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 10 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No dead occurred at all the doses tested.
- Clinical signs:
- other: The rats in all dosage groups showed sedation, dyspnoea, exophthalmus, curved position and ruffled fur. The animals recovered within 6 to 7 days.
- Gross pathology:
- No substance related gross organ changes were seen.
Any other information on results incl. tables
Rate of deaths
Dose mg/kg | Sex | No. of animals | No. of animals dead | Death rate % |
5000 | M | 5 | 0 | 0 |
6500 | M | 5 | 0 | 0 |
8000 | M | 5 | 0 | 0 |
10000 | M | 5 | 0 | 0 |
5000 | F | 5 | 0 | 0 |
6500 | F | 5 | 0 | 0 |
8000 | F | 5 | 0 | 0 |
10000 | F | 5 | 0 | 0 |
Signs and symptoms
5000 mg/kg bw
Signs and symptoms | Hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | |||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | |||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | ++ | ++ | + | + | + | + | ||||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | ||||||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | |||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
+ = slight, ++ = moderate, +++ = severe
6500 mg/kg bw
Signs and symptoms | Hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | |||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | ||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | ++ | ++ | ++ | ++ | + | + | + | + | ||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | + | |||||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | |||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
+ = slight, ++ = moderate, +++ = severe
8000 mg/kg bw
Signs and symptoms | Hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | |||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | ||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | ++ | ++ | ++ | ++ | + | + | + | |||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | + | + | ||||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | |||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
+ = slight, ++ = moderate, +++ = severe
10000 mg/kg bw
Signs and symptoms | Hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | + | + | |||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | ||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | ++ | ++ | ++ | ++ | + | + | + | |||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | + | + | ||||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | ||||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
+ = slight, ++ = moderate, +++ = severe
Bodyweight changes
Dose | 5000 | 6500 | 8000 | 10000 | |
Day 1 M | Mean BW/SD (g) | 168/4.8 | 184/12.9 | 199/12.1 | 190/7.4 |
Day 1 F | 177/3.7 | 159/7.1 | 177/3.4 | 172/5.9 | |
Day 7 M | 268/5.9 | 240/10.7 | 244/22.4 | 247/11.4 | |
Day 7 F | 209/9.5 | 185/5.5 | 203/6.0 | 198/7.9 | |
Day 14 M | 272/15.3 | 282/17.4 | 292/11.5 | 280/17.4 | |
Day 14 F | 266/9.2 | 198/6.4 | 221/10.4 | 210/11.3 |
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information According to the CLP Regulation. Criteria used for interpretation of results: EU
- Conclusions:
- LD50 > 10000 mg/kg bw
- Executive summary:
Method
The acute oral LD50 of the test item in rats of both sexes was assessed administering three doses at 5000, 6500, 8000 and 10000 mg/kg bw. Animals were observed over a period of 14 days.
Results
No dead occurred at all the doses tested. The rats in all dosage groups showed sedation, dyspnoea, exophthalmus, curved position, diarrhoea and ruffled fur; the animals recovered within 7 to 10 days.
LD50 > 10000 mg/kg bw
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.